Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Combination Therapy in Transplant Ineligible Newly Diagnosed PCNSL
NCT05998642Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Canadian Cancer Trials Group. Started Feb 2024; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05998642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998642.